While some proposed changes to how the US Food and Drug Administration regulates in vitro clinical tests will help to better protect patients, several provisions could undermine the agency’s efforts and need further clarification, according to The Pew Charitable Trusts.
In a letter to Senate Health, Education, Labor and Pensions (HELP) Committee chair Patty Murray, D-WA, and ranking member...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?